New Study Suggests Efficient Supply Drugs in U.S.

A recent study divulges into the specific ways to ensure an uninterrupted, and effective supply of essential Drugs for the American consumers. An array of factors for instance the current corporate tax rate in the U.S is why the pharmaceutical production in the nation is far more attractive than in emerging economies such as China.

The United States pharmaceutical industry can amplify its appeal through adoption of advanced technology-equipped models such as continuous manufacturing (CM). U.S. can reclaim its foothold in pharmaceutical manufacturing which has been controversial lately. The findings established by Clifford Rossi in the study funded by FDA, and Health and Welfare Services assessing the current system. Clifford Rossi is a professor at the University of Maryland with expertise in risk management.

According to Rossi, integration of medicines in the executive order by the Biden administration on U.S. supply chain is an initiating point. Rossi pointed out the current pain points that the government or the pharmaceutical manufacturing industry is trying to troubleshoot over the coming decade. For instance, currently the pharmaceutical industry is experiencing a shortage of 45 Drugs of which COVID-19 has been a critical part. As a part of the study, Rossi applied simulation analysis technique to generate analytical results across 156 domestics as well as international scenarios.

The findings highlight that continuous manufacturing is a rather economical alternative across all the scenarios as compared to conventional batch processing. The study emphasizes on the potential of CM in enhancing efficiency across supply chain.